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The Bioresource center Ghent is the central hospital-integrated biobank of Ghent
University Hospital. Our mission is to facilitate translational biomedical research by
collecting, storing and providing high quality biospecimens to researchers. Several
of our biobank partners store large amounts of cell lines. As cell lines are highly
important both in basic research and preclinical screening phases, good annotation,
authentication, and quality of these cell lines is pivotal in translational biomedical science.
A Biobank Information Management System (BIMS) was implemented as sample and
data management system for human bodily material. The samples are annotated by
the use of defined datasets, based on the BRISQ (Biospecimen Reporting for Improved
Study Quality) and Minimum Information About Biobank data Sharing (MIABIS) guidelines
completed with SPREC (Standard PREanalytical Coding) information. However, the
defined dataset for human bodily material is not ideal to capture the specific cell line data.
Therefore, we set out to develop a rationalized cell line dataset. Through comparison of
different datasets of online cell banks (human, animal, and stem cell), we established
an extended cell line dataset of 156 data fields that was further analyzed until a smaller
dataset—the survey dataset of 54 data fields—was obtained. The survey dataset was
spread throughout our campus to all cell line users to rationalize the fields of the dataset
and their potential use. Analysis of the survey data revealed only small differences in
preferences in data fields between human, animal, and stem cell lines. Hence, one
essential dataset for human, animal and stem cell lines was compiled consisting of
33 data fields. The essential dataset was prepared for implementation in our BIMS
system. Good Clinical Data Management Practices formed the basis of our decisions
in the implementation phase. Known standards, reference lists and ontologies (such as
ICD-10-CM, animal taxonomy, cell line ontology…) were considered. The semantics of
the data fields were clearly defined, enhancing the data quality of the stored cell lines.
Therefore, we created an essential cell line dataset with defined data fields, useable for
multiple cell line users.
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INTRODUCTION
In the last two decades, biobanks—specialized
infrastructures that store, annotate, and distribute
biospecimens—have emerged and professionalized through
the implementation of quality and data management systems
based on harmonized minimal datasets which allow sharing of
samples between researchers and thus enhancing progression of
clinical research (1).
In 2015, the Bioresource center Ghent—formerly known
as Bimetra Biobank (2)—established a central high quality
biobanking facility at Ghent University hospital. This hospital-
integrated biobank brought together multiple decentralized
biobank initiatives into a professionalized biobank, with
implemented quality management system.
Local strategic prospective collections, important
historical collections, and interuniversity focus collections
are operationally managed within the biobank through an
implemented biobank information management system (BIMS),
named SLims1. Current minimal datasets for these collections
reflect recommended fields from known guidelines (3–6) or
standards (7, 8) complemented with quality parameters, by use
of the “Standard Pre-analytical Code” (SPREC) (9, 10) or the
“Biospecimen Reporting for Improved Study Quality” (BRISQ)
system (11, 12), as harmonization of datasets is still ongoing
at the European (“Biobanking and Biomolecular Resources
Research Infrastructure—European Research Infrastructure
Consortium” (BBMRI-ERIC)2) and international (driven by
the International Society for Biological and Environmental
Repositories (ISBER)3) level. The samples are collected in a
project-based manner and can be used for fundamental basic
research studies, in preclinical screening phases and in actual
clinical trials.
The Bioresource center Ghent is part of the “Health,
innovation and research institute” of Ghent University Hospital,
which is a central contact point, service provider and knowledge
center for biomedical translational and clinical research and
health care innovation. The goal of translational biomedical
science—an interdisciplinary field—is to expedite health care
progress in prevention, diagnosis and treatment by combining
disciplines, resources, expertise and techniques (13). The mission
of the Bioresource center Ghent is to operate as a central contact
point, knowledge center and high-quality service provider for all
aspects related to biobanking.
Translational biomedical science is a clinical domain
supported by three main pillars: bench side, bedside and the
community. The translation of “bench side” observations into
actual clinical applications is a long and elaborate process. Before
actual clinical trials can be initiated, several basic research and
preclinical research phases have to be completed. In preclinical
screening phases, potential chemical compounds are often
screened in the lab on cell lines. Both human and animal
derived cell lines are considered as representative model systems
1Genohm, https://www.genohm.com/
2http://www.bbmri-eric.eu/
3http://www.isber.org
for studying numerous biological mechanisms and serve as
important preclinical models for drug target discovery and rapid
assessment of toxicity profiles (14).
Cell line annotation, authentication as well as the quality
of the cell line are pivotal for determining the reliability and
reproducibility of these preclinical tests. The lack of attention
given to these preclinical data is an underestimated problem in
biomedical science, leading to delays and increased costs in drug
discovery studies (15, 16). Vast warehouses of cell line samples
are available in commercial and academic settings. However, the
datasets pertaining to these cell line samples differ massively in
content and information (e.g., cell line origin, processing history)
leading to cell line misidentification, misuse, mismatching, and
the use of mixed clones by culture mix-ups (17, 18). Remarkably,
SPREC and BRISQ do not cover specific data fields for cell lines,
as they are categorized as complex derivatives, whose isolation
requires usage of multiple steps and/or addition of chemical
substances (3).
As multiple cell line collections are present on our campus,
we set out to develop a uniform, campus-wide essential cell
line dataset that tackles the issues regarding misidentification,
annotation and poor culture follow-up. Our experience with
cell lines indicated that a comprehensive cell line dataset should
ideally contain three large categories of information.
First of all, general information regarding the origin and
culture of the cell line, such as cell line name, type of
tissue, derivation method, relevant clinical, and demographic
information, cell line passage, current culture/freezing/thawing
protocols and cell line aging information is paramount (19, 20).
Secondly, information for clear authentication of the cell line
should be included. Cell line authentication relies on comparing
samples derived from the same donor (16) by Short Tandem
Repeat (STR) profiling and Single Nucleotide Polymorphisms
analysis. To our current knowledge, there is no general approved
standard or centralized online reference database for cell line
authentication using Single Nucleotide Polymorphisms analysis
(18, 21), leading to inaccuracy (22), although there is a general
consensus on the need to establish this for cell line authentication.
Thirdly, quality data should be available, such as information
regarding control of bacterial, viral, fungal of mycoplasma
contaminations of the cell cultures (23, 24).
Thus, we set out to develop a comprehensive cell line dataset
which would enhance cell line quality and their usability in
translational research..
MATERIALS AND METHODS
Establishment of the “Extensive Cell Line
Parameter Dataset”
Relevant articles regarding cell line datasets were searched in
PubMed R©. Additionally, several cell line companies, vendors and
a large cell line locator4 were identified through a general website
search. A selection of frequently used and mentioned cell banks
wasmade, taking into account that human (15 cell banks), animal
(15 cell banks), and stem cell lines (3 cell banks) were represented
4https://www.labome.com/method/Cell-Lines-Companies.html
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within the selected banks. All data fields found in the cell banks
were listed, forming the “Extensive cell line data field set.”
Evaluation of the “Extensive Cell Line Data
Field Set” and Establishment of the
“Survey Cell Line Data Field Set”
The usability of the “Extensive Cell line data field set” for
different cell types was evaluated by subdividing the dataset
fields into 6 nominative categories (named “basic cell line,”
“administrative information,” “clinical and demographic,” “cell
culture,” “genetic” and “quality/validation data” fields) and
comparing the presence of each data field per cell line type, thus
for human, animal, and stem cell lines. Data fields that were
hardly present in any cell line database were eliminated from
the survey. Subsequently, a redundancy strategy was applied to
the dataset in order to eliminate data fields in which similar
and overlapping information was captured. To identify similar
and overlapping information, the selected 15 human cell banks
were searched for a particular widely used human kidney (HEK
293, immortalized human embryonic kidney cell line) and cancer
(HeLa, immortalized cell line from cervical cancer cells) cell line.
The 15 selected animal cell banks were searched for a particular
well-known animal cell line [MC 3T3, osteoblast precursor cell
line derived from Mus musculus (mouse) calvaria cell line]. The
obtained information in each data field was listed and compared.
Subsequently, the most appropriate name for the data field was
selected to provide an as clear as possible content for the field.
REDCap (Research Electronic Data
Capture) Survey
The “Survey Parameter Set” formed the basis of a REDCap
survey (25). Survey data were collected and managed using
REDCap electronic data capture tools hosted at Ghent University
Hospital5. REDCap (Research Electronic Data Capture) is
a secure, web-based application designed to support data
capture for research studies, providing: (1) an intuitive interface
for validated data entry; (2) audit trails for tracking data
manipulation and export procedures; (3) automated export
procedures for seamless data downloads to common statistical
packages; and 4) procedures for importing data from external
sources. The survey was distributed “campus-wide” to research
groups that have cell lines to their disposition. The survey was
constructed in such a way that for each type of cell line (i.e.,
human, animal, cancer, and stem cell lines), researchers could
indicate responses, thus allowing the identification of essential
differences in the data fields per type of cell line. The researchers
were asked which parameters they retain for their cell lines at
present and if they annotate their cell lines. Additionally, they
were asked which data fields they would find relevant to be
mentioned in the campus-wide minimal dataset.
REDCap Survey Analysis
The returned survey data were thoroughly evaluated per cell
line type (human/animal/stem cell). The data fields were as
described before, regrouped in nominative categories to allow
5https://www.uzgent.be/nl/home/Paginas/home.aspx
efficient analysis of the data: Basic cell line data, clinical and
demographic data fields, cell culture data, genetic data, quality,
and validation data and administrative data. Data fields were
considered as highly relevant if more than 50% of the responders
indicated it. Fields were considered as not relevant if more than
50% of responders indicated it. Global analysis of the REDCap
survey results led to the inclusion of data fields in the rationalized
“essential cell line dataset.”
Essential Dataset: Defining the Cell Line
Dataset Template
The data fields obtained in the “essential cell line dataset” were
further evaluated and defined to allow the actual development
of a cell line dataset template. Several steps were initiated and
each data field was individually reviewed. Some fields from the
essential dataset were split into multiple fields so that one type
of data would be recorded per data field and not a combination
of data, which is a general “Good Clinical Data Management
Practice (GCDMP)” rule. This was also applied for registering
units accompanying their specific values.
The “label” or “field name” of the data fields were screened
for synonymy for which a correction was made by selecting the
least ambiguous term as “survivor.” If, after selecting the least
ambiguous term, the need for a better label still persisted, a
new label was proposed and presented to a panel consisting of
biobank data managers and two quality managers, which have
extensive experience with cell lines and cell culture. The newly
proposed terminology was compared to literature to ensure its
validity. Next, the essential data fields were defined by using the
best existing description and thus introducing definitions to the
data fields. Definitions were chosen from SPREC (10), BRISQ
(12), MIABIS (6), PubMed (MeSH) or by adjusting existing
definitions (26, 27) to best suit a biobanking/clinical context in
concurrence with propositions from the Good Clinical Practices
and the General Data Protection Regulation6. If no suitable
existing definition could be found, a new definition would be
postulated. Because of the great value of consistency in semantics,
existing definitions were always favored above newly established
definitions and if necessary, existing terms were divided into
better definable sub labels.
A full list of the withheld data fields and their definitions can
be found in Table 3.
Implementation of the Essential Cell Line
Dataset Through Use of Ontologies and
Lists Within the BIMS
Following the creation of essential data field labels and providing
a definition for the desired content of the field, the actual field
options for filing in the fields were reviewed in order to obtain
clear and consistent data. To implement and secure good data
practices, optimal use was made of “fixed choice” data fields,
with the addition of options as “not performed,” “unknown” or
“missing data.”
6https://eugdpr.org/
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Several known standards and ontologies were evaluated for
implementation: the “Cell Line Ontology” (28), “International
Classification of Diseases for Oncology (29)” and the “Biological
Classification (Taxonomy) for Class, Order and Species.” For date
and time stamps, the ISO 8601 standard7 was implemented and
all units were collected through the use of the “International
System of Units” (30). Preference was given to known standards
if these were practical in use. If no appropriate standard could
be found or was deemed suitable for our setting, data fields
with a well-defined fixed choice list were implemented. By the
combination of standards and ontologies, all elements of essential
sample information were collected and stored in a structured and
well-approved manner.
RESULTS
Establishment of the Different Datasets
The Extensive Cell line parameter dataset was established
as described in the Materials and methods section. Datasets
used by different companies and described in articles were
extracted and listed for comparison. This led to a dataset
of 156 different data fields, visible in Table 1. All data
fields in Table 1 are listed alphabetically. Subsequently, we
divided the data fields in nominative categories (“basic cell
line,” “administrative information,” “clinical and demographic,”
“cell culture,” “genetic”, and “quality/validation data”) and a
redundancy strategy was applied to reduce overlapping data. This
led to a reduction of 65% of fields, resulting in 54 remaining data
fields. The most appropriate name was chosen for overlapping
data fields and the resulting set formed the survey cell line
parameter dataset (Table 2).
Survey Results
A REDCap survey was designed using the survey cell line
parameter dataset. The survey results cover the global responses
of 17 different research groups on our campus. Figure 1 gives an
overview of the received responders according to cell type origin.
Responses showed that 57.1% of the respondents exclusively store
human cell lines and 14.3% exclusively work with animal cell
lines. 28.6% of the respondents work with both human and
animal cell lines. Within the respondents that work with human
cell lines (85.7%), all respondents have human cancer cell lines
and 14.3% work additionally with human stem cell or induced
pluripotent stem cell lines. Within the respondents that work
with animal cell lines (42.9%), 7.1% work with animal stem cell
or induced pluripotent stem cell lines.
As cell line authentication is essential for good cell line
practices, we also inquired if cell line authentication was
performed before use of cell lines in experiments. Figure 2
shows their perspective regarding their performance of cell line
authentication practices. This demonstrates that <35% of the
responders authenticates the cell lines they are using.
Next, the survey data field list was analyzed per type of
cell line, i.e., human, animal, and stem cell line. In order
to be able to compare the results, the data fields were
7https://www.iso.org/obp/ui#iso:std:iso:8601:-1:dis:ed-1:v1:en
subdivided in 6 grouped categories: “basic cell line information,”
“clinical and demographic data,” “cell culture information,”
“genetic characteristics, quality,” “validation and administrative
information.” The responders had the option to indicate if they
found a field “Highly relevant,” “neutral” or “not relevant.” A
cut-off point was set at 50%, meaning that if more than 50%
of the responders found a field “highly relevant,” it should be
included into the final dataset. Furthermore, if more than 50% of
the responders found the field “not relevant,” it will not be include
in the final dataset.
Figure 3 gives an overview of the relevance scores for the
basic cell line data fields. A line was used for indicating the
50% relevance cut-off point. Analysis of the basic cell line data
fields shows that most fields are considered as highly relevant,
regardless of the cell line type. As can be seen, the fields
“Cell type,” “Organism” and “Tissue origin” got the overall best
relevance score. “Cell type” was the only field with a perfect score
over the 3 types of cell lines. The field “derivation” is considered
as neutral for human and animal cell lines, though highly relevant
for stem cell lines. “Amount and cell conc” divides researchers
of animal cell lines between “Neutral” and “Highly relevant.”
Overall could be noted that these fields are extremely relevant
for stem cell lines. Eight of the ten fields received a 100% highly
relevant score, however all fields received a good to excellent
score for all three types of cell lines.
Figure 4 gives an overview of the clinical and demographic
data fields. Within the clinical and demographic data, regardless
of cell line type, “Illness, Age and Gender” are considered as
highly relevant fields. Differences in relevance of the datafields
can be seen depending on the type of cell line. Ethnicity is
only viewed as highly relevant for stem cell lines, and as
neutral for human and animal cell lines. Additional clinical and
demographic data fields are seen as neutral.
Figure 5 gives an overview of the cell culture datafields.
Differences can be observed between the cell line types. Most
data fields (15 out of 18) are considered as highly relevant for
human cell lines, except for anticoagulant use, growth medium,
and freezing medium composition that are considered as neutral.
Data analysis for animal cell lines is almost identical with the sole
exception that growth medium additives are also considered as
neutral. The relevance of cell culture data fields for stem cell lines
differs, showing that only 9 out of 18 data fields are considered
as highly relevant. Neutral data fields are: anticoagulant use, lot
number registration, supplier registration, subculture protocol,
freezing medium composition, freezing storage temperature,
cryovial type, thawing method, and culture temperature.
Figure 6 gives an overview of the genetic data fields. There
is overall variation in fields that are considered as relevant
between all cell line types. In general, for each cell line type,
half of the data fields is considered as relevant, the other half
as neutral.
Figure 7 gives an overview of the quality and validation data
fields. Microbial screening status and mycoplasma screening are
considered as highly relevant for all cell types. Viral quality
control is also considered as highly relevant for human cell lines
and stem cell lines. STR profile is also rated as highly relevant
for animal cell lines and stem cell lines. Additionally, DNA
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TABLE 1 | Extensive cell line data field set.
General cell line
information
Administrative
information
Clinical and
demographic
information
Culture method
information
Validation and quality
control information
Genetic information
Achor-dependancy Analyse certificate Age Acclimatation of cells Bacteria Antigen expression
Advantages Applications + advice Age at collection Antibiotic resistance Biosafety guidelines Antigen expression
(surface)
Alias Available product formats Case history Antibiotics Biosafety level Cell line stability
Animal Catalog number Clinical data Anticoagulant DAPI Cytogenetics
Brief description Cell culture images Diagnosis information Atmosphere Flow cytometry Details karyotype
Cell line alias Comments Disease Cell density (cells/cm²) Fungi DNA Fingerprint
Cell line biological
properties
Compliance with
regulations
Donation frequency Cellular products Hazard ELISA
Cell line description Compliance with
standards
Donor criteria CO2 concentration Health hazards of liquid
nitrogen
Genes expressed
Cell line origin Delivery forms Ethnicity Complete growth medium Microbiological culture Genetic alteration
Cell type Distribution Ethnicity information Cryovial MSDS file Genetics
Clonality Effects Gender Culture conditions Mycoplasma Immunology
Genus Images Harvest of cells Derivation Personal protective
equipment
Isoenzymes
Identity Limited use Histopathology Doubling time Safety precautions Karyotype
Lifespan Limited warranty Metastasis Freeze concentration Sterility Mutational status
Morphological character MTA agreement Organ of metastasis Freeze medium Sterility tests Oncogene
Morphology Name of depositor Pathology Incubation Storage precautions Pathway activation
Organism Originator Preparation organ Medium Tryptan-Blue exclusion PCR assay
Species Ownership + patents Race Medium renewal
frequency
Validation assay Profile
Species validation Permissions And
Restrictions
Screened before donation Passage Viable cell count Receptor expression
Strain Price Sex Passage number Viruses Receptors
Tissue Provider Tissue form Protocol for cell culture Reprogramming method
Tissue origin References Weight Protocol for cell thaw Reverse transcriptase
Register Protocol for culture
medium preparation
RNA hybridization
Regulation Protocol for freezing cells STR profile
Related products Protocol for maintenance Transformation
Shipped in Protocol for subculturing Tumorigenic
Shipping table +
distribution notes
Quantity and
concentration
Video + resources Required materials
Year of origin Split ratio
Storage conditions
Storage temperature
Subcultivation ratio
Subculture routine
Subculturing
Subculturing protocol
Temperature
Thawing method
fingerprinting is also highly relevant for stem cell lines. The other
data fields are considered as neutral.
Figure 8 gives an overview of the administrative data fields.
For human and animal cell lines, these are generally considered
as neutral. For stem cell lines, the Material Transfer Agreement
(MTA) is highly relevant. However, conformity with regulations
is regarded as not relevant.
As analysis of the relevance of the data fields between human,
animal, and stem cell lines showed that no parameters are deemed
completely irrelevant in either type of cell line and a large overlap
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TABLE 2 | Survey cell line data field set.
Data field Nominative category Data field Nominative category
Adhesion Basic cell line Growth medium Additives Cell culture
Age Clinical and demographic Growth medium Composition Cell culture
Amount and cell conc Basic cell line Illness Clinical and demographic
Antibiotic resistance Cell culture Immunology Genetic
Antibiotics Cell culture Isoenzyme validation Quality/validation data
Anticoagulant use Cell culture Lot number registration Cell culture
Antigen expression Genetic Medium renewal (sub cultivation) Cell culture
Biosafety Basic cell line Microbial screening status Quality/Validation data
Cell line stability Cell culture Morphology Basic cell line
Cell type Basic cell line MTA agreement Administrative information
Cellular products Genetic Mutational Status Genetic
Clinical data Clinical and demographic Mycoplasma Screening Quality/validation data
Conformity with regulations Administrative information Organism Basic cell line
Cryovial type Cell culture Passage number Basic cell line
Culture atmosphere Cell culture Patents and properties Administrative information
Culture temperature Cell culture Receptor expression Genetic
Cytogenetics Genetic Reprogramming method Genetic
Derivation Basic cell line Short tandem repeat profile Quality/validation data
Details karyotype Genetic Sub cultivation ratio + cell
density
Cell culture
Dna fingerprint Quality/validation data Subculture protocol Cell culture
Doubling time Cell culture Supplier registration Cell culture
Ethnicity Clinical and demographic Thawing method Cell culture
Freezing medium composition Cell culture Tissue origin Basic cell line
Freezing storage temperature Cell culture Transformation Basic cell line
Gender Clinical and demographic Tumor details Genetic
Gene expression Genetic Tumor formation Genetic
GMO status Genetic Viral quality control Quality/validation data
in relevance exists. Thus, we concluded to develop one dataset,
useable for all three types of cell lines. All fields were retained and
categorized into four levels. The basic and crucial data fields (level
1) consist of highly relevant fields, mandatory for all cell lines.
The fields containing data related to certain procedures, quality
processes or performed analysis can be found in level 2 and are
considered as optional to fill in. Level 3 data is data pertaining
to biobanking activities, such as operational, administrative and
storage information. These data fields are completed by biobank
staff members, and are also considered mandatory to fill in.
Finally, all data that can be calculated or automatically filled in
by the BIMS system has been classified as level 4 data.
From a GCDMP perspective, the data fields, regardless of their
level, were further reviewed one by one,: units were separated
from numbers and fields in which grouped data responses were
expected were divided in multiple fields to capture one type of
data per field. This led to an increase in amount of data fields
in the dataset, though a better resulting data quality. Next, a
clear and understandable “label” or “field name” was selected
and a definition was added, to clarify the intended data response.
Overall, this approach resulted in multiple changes in the dataset.
The “Organism” field has been relabeled to “Species” reducing
ambiguity. In addition two extra fields -“Class” and “Order”—
were added, which are automatically filled in when the species
is selected into the “Species” field. Further, the fields “Tissue
origin” and “Morphology” were evaluated and encompassed by
the following fields: “Cell type,” “Cell line name” and “Anatomical
location.” The field “Biosafety” was relabeled to “Biosafety level,”
“Illness” to “Disease” and the fields “Age,” “Gender,” “Passage
number” and “Ethnicity” were preserved. “Amount and cell
concentration” were split into the fields “Amount (volume),”
“Amount (volume) unit,” “Amount of cells,” “Amount of cells
unit,” and two calculated fields “Cell concentration” and “Cell
concentration unit.”
Multiple cell culture data fields were adapted for good data
capture. “Adhesion” was relabeled as “Growth mode” as this field
captures information regarding adherent or suspension culture
and the label was deemed more appropriate. The field “doubling
time” was split into a field capturing the number and the time
unit. The fields “Culture atmosphere,” “Culture temperature” and
“Antibiotic resistance” were kept as is and the field “Antibiotics”
was changed to “Antibiotic addition” and “Medium renewal”
Frontiers in Medicine | www.frontiersin.org 6 June 2019 | Volume 6 | Article 137
T’Joen et al. Cell Line Dataset
FIGURE 1 | Overview of the percentage of responders vs. the type of cell line they manage.
was relabeled to “Medium renewal frequency” in order to avoid
misinterpretation. The fields “Growthmedium composition” and
“growth medium additives” were subdivided in multiple fields
labeled: “Basal culture medium,” “Serum (or alternative),” “% of
Serum (or alternative),” “Growth medium additives,” “Growth
factors” and “Remarks on culture medium.” “Sub cultivation
ratio” was renamed to “Split ratio” and “subculture protocol”
was renamed to “Cell dissociation agent or technique.” A
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FIGURE 2 | Overview of the percentage of responders that indicated to perform cell line authentication on their cell lines.
similar approach was applied to the field of “Freezing medium
composition.” The following fields were created to encompass
all data: “Basal Freezing medium,” “Serum (or alternative) in
freezing medium,” “Cryoprotectant,” “% of cryoprotectant” and
“Freeze protocol.” “Freezing storage temperature” is renamed
to “Storage temperature” and “Cryovial type” to “Storage
container.” A date and time stamp “Freeze date and time”
was also added to enhance the data value. The field “Thawing
method” was split into “Basal thawing method,” “Serum (or
alternative) in thawing medium,” “% of serum (or alternative) in
thawing medium, “Thawing stabilizer,” “% of thawing stabilizer”
and “Thawing temperature.”
To obtain clear data in the database, the fields related to
quality control and genetic information were often split in
multiple fields where the first field indicated if the analysis was
performed and the second field with which technique/method,
e.g., “Mycoplasma screening” became “Mycoplasma screening”
and “Mycoplasma screening method.” This applied for “Antigen
expression,” “DNA fingerprint” and “Viral quality control.”
The field “Gene expression” was split into multiple fields,
as mentioned above however as this field encompassed more
complex information, 5 fields were created to capture this in
a structured way. The fields “Cytogenetics/karyotype,” “GMO
status” and “Tumor formation” were defined and by the use of
fixed options there was no need to further separate the fields.
Before the cell line dataset was released for use on our
campus, some additional fields were added to allow the practical
implementation. The field “provider” is a field to identify who is
bringing in the samples. Each collaborator of the biobank receives
a unique number from the Bioresource center upon signing of
the service level agreement. Additionally, the collaborators can
use the fields “Biobank subcollection ID,” “study specific patient
ID,” “Adremanumber,” “Reference ID,” “collection center” and
“Visit number” to further define specific information regarding
their collection. The fields “Status” and “date and time of
registration” are filled in by the biobank personnel, as is the
information regarding the location of the samples which are
defined by the fields “Location path,” “Location,” “Row” and
“Column.” Some open text fields are added to capture important
additional information: “Remark of group,” “Sample remarks”
and “Comment.”
A section of fields to encompass information regarding 2D
and 3D culture on biomaterials was also included to be filled in
optionally, as there is a large biomaterial and tissue engineering
consortium present on our campus which uses multiple cell lines
for their experiments.
To have an easily fillable, consistent and searchable database,
the use of “fixed choice fields” was introduced. If ontologies and
standard classifications/lists were available, the user-friendliness
was reviewed. E.g., for designing a list of cell types a concise
selection of different cell types was made out of the “Cell Line
Ontology: CLO” (28, 31) as reference. These cell types will
be combined with their anatomical location in an additional
data field, based on the topology code of the “International
Classification of Diseases for Oncology” (29) and for ease of
use the high level of anatomic location was implemented (“Lip”
instead of “External upper lip” etc.). The applied ontologies and
standard lists that were considered, can be found in Table 3,
under column “Standards/principles for data quality.”
The resulting cell line data set consists of a total of 101
data fields. The majority of these fields (58 out of 101 data
fields) are level 1 fields, thus mandatory to complete by the
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FIGURE 3 | Overview of the relevance score of basic cell line data fields for each type of cell line. A cut-off line at 50% is visible, indicating which data fields are
generally considered as highly relevant or as not relevant.
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FIGURE 4 | Overview of the relevance score of clinical and demographic data fields for each type of cell line. A cut-off line at 50% is visible, indicating which data
fields are generally considered as highly relevant or as not relevant.
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FIGURE 5 | Overview of the relevance score of cell culture data fields for each type of cell line. A cut-off line at 50% is visible, indicating which data fields are generally
considered as highly relevant or as not relevant.
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FIGURE 6 | Overview of the relevance score of genetic data fields for each type of cell line. A cut-off line at 50% is visible, indicating which data fields are generally
considered as highly relevant or as not relevant.
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FIGURE 7 | Overview of the relevance score of quality and validation data fields for each type of cell line. A cut-off line at 50% is visible, indicating which data fields are
generally considered as highly relevant or as not relevant.
Frontiers in Medicine | www.frontiersin.org 13 June 2019 | Volume 6 | Article 137
T’Joen et al. Cell Line Dataset
FIGURE 8 | Overview of the relevance score of administrative data fields for each type of cell line. A cut-off line at 50% is visible, indicating which data fields are
generally considered as highly relevant or as not relevant.
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TABLE 3 | Essential cell line dataset.
Data field label Level Data type Principles for data quality Definition
Species 1 Fixed choice Biological classification (taxonomy) for
class, order and species
Species from which the animal cell line was
derived
Class 4 Automatic completion Biological classification (taxonomy) for
class, order and species
Order 4 Automatic completion Biological classification (Taxonomy)
for class, order and species
Cell type 1 Fixed choice Cell Line Ontology (CLO) Cell line cell type.
Cell line name 2 Free text field The International Cell Line
Authentication Committee (ICLAC)
Name of the (commercial) cell line.
Tissue origin/anatomic
location
1 Fixed choice Anatomical location/origin of the sample.
Biosafety level 1 Whole number Biological safety levels are ranked from one to
four and are selected based on the agents or
organisms on which the research or work is
being conducted. Each level builds up on the
previous level, adding constraints and barriers.
The classification of your organism can be
checked at https://www.biosafety.be/content/
tools-belgian-classification-micro-organisms-
based-their-biological-risks
Growth mode 1 Fixed choice Growth mode of the cell culture.
Disease 1 String (restricted
format)
Diseases for Oncology (ICD-O) ICD10 code of the studied disease where for
the sample was collected, https://icd.who.int/
browse10/2016/en
Gender 1 Fixed choice This indicates the gender of the
participant/animal. “Unknown” means
information about the gender was missing,
“Other” stands for transgender/gender neutral
participants.
Ethnicity 2 Fixed choice A large group of people who have the same
national, racial, or cultural origins, or the state
of belonging to such a group.
Study specific patient
ID
2 Free text field The link to the patient (according to the patient
identification log) (pseudonomized).
Adremanumber 2 String (restricted
format)
Directly identifying patient identification code
provided by UZ Gent.
Reference Id 2 Free text field
Collection center 2 Fixed choice This field contains the location where the
sample was collected from the patient. It allows
identification of multiple collection centers (e.g.,
hospitals or general practice centers).
Collection date and
time
2 Date ISO 8601 Date and time of collection.
Consent status 1 Fixed choice The consent status of the participant regarding
the sample.
Sample status on
arrival
1 Fixed choice Status of your sample at arrival in the Biobank
facility.
Visit number 2 Whole number This contains the visit number. E.g., 0 stands for
the baseline visit.
1 is the first visit after the baseline visit.
Type 1 Fixed choice This describes the content type of the sample.
Passage number 1 Whole number A record of the number of times the culture has
been subcultured, i.e., harvested and reseeded
into multiple ‘daughter’ cell culture flasks.
Amount (volume) 1 Whole number
Amount (volume) unit 1 SI units International system of units (SI)
Amount of cells 1 Whole number
(Continued)
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TABLE 3 | Continued
Data field label Level Data type Principles for data quality Definition
Amount of cells unit 1 SI units International system of units (SI)
Cell concentration 4 Calculated field
Cell concentration unit 4 SI units International system of units (SI)
Culture atmosphere 1 Fixed choice The controlled atmosphere in which the cells
are cultivated (CO2/O2 levels).
Culture temperature 1 Fixed choice The controlled temperature at which cells are
cultivated.
Basal culture medium 1 Fixed choice The basic unsupplemented medium which
promotes the growth of many types of cells.
Serum (alternative) 1 Fixed choice Serum or alternative that contains a complex
array of protein components, essential for cell
culture.
% of serum (alternative) 1 Decimal number Percentage of serum used in culture medium.
Growth medium
additives
1 Fixed choice Additional supplements to the basic culture
medium that provide optimal growth conditions
for the specific cell line.
Growth factors 1 Fixed choice Additional growth factors to the basic culture
medium that provide optimal growth or
differentiation conditions for the specific cell
line.
Antibiotic addition 1 Fixed choice Antibiotics that are added to routine culture
medium.
Antibiotic resistance 1 Fixed choice Antibiotics for which the cell line is resistent.
Remarks culture
medium
2 Free text field Extra information concerning the culture
medium.
Cell dissociation agent
or technique
1 Fixed choice Agent or technique used for dissociation of
cells.
Split ratio 1 Fixed choice The divisor of the dilution ratio of a cell culture
at subculture, e.g., 1/5.
Doubling time 2 Time ISO 8601 The period of time required for the cells to
double in amount.
Doubling time unit 2 SI units International system of units (SI)
Seeding cell density 1 Whole number Density/concentration at which the cells are
seeded after passaging.
Seeding cell density
unit
1 SI units International system of units (SI)
Medium renewal
frequency
1 Fixed choice Frequency of culture medium renewal.
Cell Line Stability 2 Fixed choice Indication of cell line stability.
Basal Freezing Medium 1 Fixed choice The basic unsupplemented medium which
forms the essential part of the freezing solution.
Serum (alternative) in
freezing medium
1 Fixed choice Serum or alternative that contains a complex
array of protein components, used to
supplement the basic freezing medium.
% of serum (alternative)
in freezing medium
1 Decimal number Percentage of serum used in freezing medium.
Cryoprotectant 1 Fixed choice A cryoprotectant is a substance used to
protect biological tissue from freezing damage.
% of cryoprotectant 1 Decimal number Percentage of cryoprotectant used in the
freezing medium.
Freeze protocol 1 Fixed choice Technique used for freezing the sample.
Conservation 1 Fixed choice
Basal thawing medium 1 Fixed choice The basic unsupplemented medium which
forms the essential part of the thawing solution.
Serum (alternative) in
thawing medium
1 Fixed choice Serum or alternative that contains a complex
array of protein components, used to
supplement the basic thawing medium.
(Continued)
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TABLE 3 | Continued
Data field label Level Data type Principles for data quality Definition
% of serum (alternative)
in thawing medium
1 Decimal number Percentage of serum used in thawing medium.
Thawing stabilizer 1 Fixed choice Supplements added to the thawing medium to
stabilize the cells during the thawing process.
% of thawing stabilizer 1 Decimal number Percentage of thawing stabilizer in thawing
medium.
Thawing temperature 1 Fixed choice Temperature at which the samples are thawed.
Adapted to 3D culture 1 Y/N; Fixed choice Has the cell line been adapted to 3D culture?
Feederlayer 1 Y/N; Fixed choice Is a feeder layer needed for cell culture of the
cell line?
Feederlayer
determination
2 Free text field Which feeder layer is needed for maintaining
the cell culture of the cell line?
Biomaterial (basic
composition)
2 Fixed choice
Biomaterial
modification
2 Fixed choice
Biomaterial coating 2 Fixed choice
Remark of group 2 Free text field Extra remarks related to the cell line.
Sample remarks (QC) 2 Free text field Remarks concerning the quality of the specific
sample.
Comment 2 Free text field General comment (cannot contain identifying
data).
Storage temperature 1 Fixed choice Temperature at which sample is stored.
Storage container 1 Fixed choice Type of container in which the sample is store
for long term storage.
Freeze date and time 1 Date ISO 8601 Date and time of freezing of the sample.
Cytogenetics/karyotype 1 Fixed choice Method used for karyotyping/ Cytogenetic
procedures.
Antigen expression 1 Fixed choice Is there antigen expression within the cell line
sample?
Type of antigen
expression
2 Fixed choice What type of antigen expression can be
observed?
Method of antigen
expression
2 Fixed choice Method used for determining the antigen
expression profile.
Reprogramming
method performed
1 Fixed choice Was the cell line obtained through a
reprogramming process?
Reprogramming
method
2 Fixed choice Which method was used for reprogramming
the cell/line.
GMO status 1 Fixed choice Is the cell line classified as a genetically
modified organism?
Microbial screening
status (microbial
contamination)
1 Fixed choice Was the sample screened for microbial
contamination and what was the result of this
screening?
DNA fingerprint 1 Fixed choice The American National Standards
Institute (ANSI), American Type
Culture Collection (ATCC)
Has a DNA fingerprinting method been
performed?
DNA fingerprint
(method)
2 Fixed choice The American National Standards
Institute (ANSI), American Type
Culture Collection (ATCC)
Which screening method was used for DNA
fingerprinting?
Viral quality control 1 Fixed choice Has the cell line been screened for viral
contamination?
Viral quality control
(method)
2 Fixed choice Which method was used for the viral quality
control?
Mycoplasma screening 1 Fixed choice Has the cell line been screened for
mycoplasma contamination?
Mycoplasma screening
(method)
2 Fixed choice Which screening method was used for the
Mycoplasma detection?
(Continued)
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TABLE 3 | Continued
Data field label Level Data type Principles for data quality Definition
Tumor formation 2 Fixed choice Ability for tumor formation.
Gene expression level 2 Fixed choice
Gene expression level
(test)
2 Free text field
Gene expression
analysis method
2 Fixed choice
Gene expression
overexpression method
2 Fixed choice
Gene expression
inhibition method
2 Fixed choice
Provider 1 String (restricted
format)
Provider number given by Bioresource center
Ghent (unique for the biobank)
Biobank subcollection
ID
2 Free text field Field that can be used to indicate specific
subprojects in which the samples are collected
Status 3 Fixed choice Operational status of sample (Bioresource
center Ghent)
Date and time of
registration
3 Date ISO 8601 Date of registration in the biobank
Location path 3 Fixed choice Location of the sample including subdivisions
(freezer, shelf, rack…)
Location 1/3 Fixed choice Box number
Row 1/3 Fixed choice Row within the box in which the sample is
located
Column 1/3 Fixed choice Column within the box in which the sample is
located
Cell line formation 2 Free text field Description creation of the cell line.
researcher. There are 32 optional (level 2) data fields that allow
to enhance the data quality, 7 level 3 fields that are filled in by the
biobank staff and four automatic calculated fields (level 4). The
dataset fields were configured in our BIMS system. Through an
Excel template with the configured option lists, the information
can easily be received from the researchers and put into the
BIMS system.
DISCUSSION
Cell lines are essential in translational biomedical science.
Misidentification, culture mix-ups, authentication and
annotation issues often occur, hampering and delaying the
reliability and reproducibility of preclinical tests, which are
mandatory before the initiation of actual clinical trials. Accurate
documentation of cell line data in a state-of-the-art database
system is critical to ensure the credibility, reproducibility,
and translation of data and results from cell culture-based
experiments (17).
The need for international standards to close multiple gaps
in this field is obvious. In order to resolve this issue, the first
steps to harmonization are being initiated as new standards are
arising [human cell line STR profiling (32) (ASN-0002), DNA
barcoding for animal cell lines (13) (ASN-0003)]. Additionally,
an effort was made to make cell line misidentification more
conspicuous with the establishment of “The International Cell
Line Authentication Committee (ICLAC).” They established
controlled vocabularies and ontologies for already existing cell
lines. However, a reduction in complications and redundancies
in the literature concerning cell lines didn’t seem attainable (15).
At our campus, multiple cell lines are kept in biobanks. The
need for a uniform, campus-wide cell line dataset that tackles
issues regarding misidentification, annotation and poor culture
follow-up is high. We initiated this process by a large-scale
literature and public database review of cell line datasets. There is
an enormous lack of clear information in literature regarding cell
line datasets and the fields these contain. A compiled extensive
dataset was established as described in theMaterials andMethods
section. There is a massive difference in available information in
the datasets pertaining to cell lines, as some vendors/repositories
only list 8 data fields and others over 50 data fields regarding
the same cell line. Further analysis through the redundancy
strategy approach, revealed additionally a lack of standardization
in terminology and definitions of the data field and the use of
divergent labels for identical field information. It is clear that
currently, different cell line repositories have established their
own divergent sets of data fields without any verification or
mutual agreement on which data should be recorded.
Through use of the redundancy strategy, a concise set of 54
data fields could be compiled for the survey dataset. As our
aim was also to examine which data researchers are currently
registering and which quality checks they are performing, we
included these questions into the REDCap survey. The REDCap
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tool allows integration of all these parameters in a survey of
reasonable length, which can be completed in a user-friendly way
by the researchers. No comments about the setup of the survey
or any remarks about difficulties completing the survey were
received. Responses from human, animal, and stem cell line users
were received, which allowed us to evaluate different expectations
and needs regarding the datasets for human, animal and stem
cell lines. Remarkable, over 75% of the cell line users do not
authenticate their cell lines.
A general consensus could be observed regarding the high
relevance of the basic cell line data fields, which was expected.
These fields were also present in the datasets of the majority of
all vendors/cell line depositors. The relevance of the clinical and
demographic related data fields varies more, but is considered
more as neutral. Cell culture information is considered as highly
relevant or neutral. The pattern of relevance for human and
animal cell lines is quite comparable. There is more distinction
with stem cell lines, where certain parameters are considered
as either very relevant or completely neutral. Some vendors/cell
line depositors give only minimal information related to cell line
culture parameters, or allow for the upload of culture protocols
to be distributed upon request of the cell line.
Genetic data information is in general less prominent in
datasets of vendors/cell line depositors, and is also mostly
considered as neutral to relevant. Genetic information is
prominent available when buying specific animal cell line clones,
engineered for certain research purposes. It is clear however, that
information related to the mutational status is necessary for stem
cell lines. Quality and validation information is rarely available.
It is assumed that some large vendors have quality and validation
procedures in place, though no specific information can be given
upfront, only upon request. One exception clearly standing out
is the German collection of Microorganisms and cell cultures,
hosted at the Leibniz Institute8. Clear information regarding
the performed tests and results can be found online, e.g.,
Mycoplasma screening by PCR, DNA fingerprinting and type
of performed PCR for revealing the STR profile, PCR analysis
for several viral contaminants. This is crucial information when
the cell lines are used in pre-clinical assays. Administrative
information detailing the proposed use, warranties, limitations
and restrictions of the material are considered as neutral. From a
legal perspective, however, this is an exceptional important part
of information and essential to keep track of, therefore these data
fields will be kept in the developed dataset. Our analysis showed
that the development of one dataset for the different types of cell
lines would be applicable and usable for our local cell line users.
A list of data fields was compiled, based on the REDCap
survey. Within this list, every single entry was subsequently
evaluated based on score, relevance and multiplicity. In the
survey, certain broad terms were used to describe the content
of data field. These fields were split in more clearly definable
sub-data fields according to GCDMP rules.
Two essential aspects to obtain good structured data are
clear and unambiguous naming of the defined data fields and
thoughtfully chosen definitions of the data fields.
8DSMZ: https://www.dsmz.de/home.html
The definitions implemented were based upon terminology
used in three known biobanking data categorizing systems:
SPREC, BRISQ, and MIABIS. SPREC and BRISQ are both
proposed as a set of recommendations for reporting data
elements of human biospecimens used in biomedical research
with the difference that SPREC allows generating a code based
on the pre-analytical processing of the samples (33). MIABIS,
as its name suggests, is an attempt to unify sample data in a
way that simplifies communication and exchange of samples
(and sample information) in a clear and non-ambiguous way (6).
The applicable definitions out of these standards were retained
for implementation, although sometimes the formulation was
simplified. Additionally, specific definitions that were not present
in the standards were designed (e.g., especially for cell culture
specific fields) based upon general accepted definitions out of
histology and cell culture handbooks (34, 35).
The data quality was further enhanced through the
implementation of standards and ontologies, and through
the use of fixed fields, thus allowing limited options per field.
Another measurement undertaken to maintain good data
practice was the possibility to distinct missing data from empty
“not filled in” data fields. For instance, within the selection list
of the fixed choice data fields an option for missing data, e.g.,
not performed, unknown etc., was included. It is taken into
account, however, that certain options might be to restraining to
be able to input the data, thus, if this would occur, the biobank
collaborators have the possibility to request additional options
for a field. The request will be reviewed by a cell line advisory
board, consisting of data managers and cell line experts. This is
especially true for new and rapid expanding fields of research,
for example the use of (bio)polymers in tissue engineering.
Bearing this in mind, the complete data set will be implemented
on campus with notification of the possibility to propose
relevant additions to fixed choice fields. The complete set of
defined options can be procured by contacting the Bioresource
center manager.
The essential dataset consists of certain fields that are linked
to each other, e.g., “Class,” “Order” and “Species.” To enhance
the user-friendliness of the dataset, it was decided, through
gathered experience weighed against literature-based study9 (36),
to include the most commonly used organisms in research
studies and not entire ontology lists. Additionally, when selecting
the “Species” in the dataset, the related “Class” and “Order”
are automatically completed in the database. This automatic
completing of fields is also the case for the calculation of “cell
concentration” and the unit based on “volume” and “amount
of cells”.
For ethnicity (37), which is more important for human based
cell lines, a compact classification was designed based on existing
classifications10 (38) and the most common nationalities in
Belgium (39–41). Statistics concerning citizens with a different
ethnical background residing in Belgium can be found online,
provided by the government. We finally designed a compact
9https://www.thermofisher.com/be/en/home/technical-resources/cell-lines.html
10https://www.ethnicity-facts-figures.service.gov.uk/ethnicity-in-the-uk/ethnic-
groups-and-data-collected
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list of 29 different ethnicity options adapted to the Belgian
population including persons who identify themselves with more
than one social group. In case the Belgian population changes,
extra options may be added. Other fixed choice lists were based
on existing data fields from other data capturing systems.
Although useful as they are, and taking into account GCDMP
guidelines, most of the withheld SPREC data fields needed
to be subdivided to create clean and unambiguous data. For
example, the SPREC field “Long term storage” which contained
the temperatures at which a sample can be stored, the methods of
storing the sample (Liquid Nitrogen (LN), Ultra low temperature
(ULT) freezing, . . . ), as well as the type of container used
for storing the sample had to be split. It was subdivided into
“Conservation,” encompassing the type of conservation (LN,
ULT,. . . ), “Storage temperature” en “Storage container.” In the
same way the fields “Type of collection” (SPREC) and the
non SPREC fields “Mode of transportation” and “Thawing
procedure” were divided into numeric (temperature, time, . . . )
fields and full text (protocol) fields. The use of these existing
standards by researchers globally increases harmony and quality
in biospecimen reporting in general.
Only minimal clinical and demographic information is
present in our cell line dataset. We do, however, recognize the
importance of this type of data relating to biobank samples
but chose to collect these data in clinical registries, linked with
the BIMS system. For clinical registries, REDCap, the tool that
was used to perform the survey, can also be used. It allows
capturing clinical and demographic information in a structured
and easy way, by designing multiple forms that can be filled in at
different time points. Additionally, sample data can be linked to
the relevant clinical and demographic information present at that
specific time point.
We chose to combine a system for sample data with
one for clinical and demographic information, thus storing
all the relevant data necessary for research in divergent
but interconnected systems. This differs from other data
capturing methods such as BRISQ where both sample and
clinical/demographic information are encompassed within all
three tiers (levels of importance to report) in one system. The
main advantage of this type of data collection lies in the fact
that all data concerning the sample is linked to the sample
itself. The downside however, is that potentially large amounts
of data are stored per sample. Additionally, many of the fields
within the BRISQ tiers allow for free text data input, opening the
possibility of clouding the data through less than optimal data
management practices.
Furthermore, in Europe, addition of clinical and demographic
data could make it possible to identify patients by specific
information, such as birthdate, specific disease etc., which is
not conform the General Data Protection Regulation guidelines.
Thanks to the REDCap software, a clear distinction can be made
between clinical and demographic data and the essential pre-
analytical data concerning the sample itself in accordance with
local legislation. This allows for researchers to use the REDCap
tool as a Case Report Form and put an extra focus on sample
specific data, which all too often is only an afterthought in
the data capturing process. Altogether, a separation between
clinical/demographic information and pre-analytical sample
specific data will elevate sample-specific data quality and
improve reproducibility.
The cell line dataset that was created, captures the most
important information related to cell lines. The database
allows distinction between clones of cell lines cultured in
different settings, frozen and thawed with different procedures,
products and methods and those that were kept on feeder
layers, coatings or biomaterials. Additionally, the inclusion of
genetic information and quality information makes the dataset
extremely valuable.
Capturing this informations assures that cell line reactions
observed in preclinical tests are in reality related to the performed
test and not to “metadata,” meaning to possible contamination
of the cell line, misidentification of the cell line or culture mix-
ups. Clear cell line identification, in which genetic parameters of
the cell lines are included, also lead to the correct use of the cell
lines combined with certain specific test substances created for
personalized medicine approaches or disease-specific solutions.
The dataset will be evaluated after one year of use. A
customer satisfaction survey will be sent out to all our cell
line users, who hopefully will be enthusiastic about the changes
made. Based upon their feedback, additional changes could
be made to the survey. As our biobank is part of the
Biobanking and Biomolecular Resources Research Infrastructure
of Belgium11, we will discuss spreading this dataset within our
network to allow a broader use within Belgium as part of the
ongoing harmonization strategies related to data management
and quality.
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